Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

This study is testing whether a specially engineered virus (Ad-TD-nsIL12), injected directly into newly diagnosed diffuse intrinsic pontine glioma (DIPG) tumors in children, can stimulate the immune system and fight the cancer. This is an early-phase trial assessing safety and initial effectiveness for children who have not yet received any treatment. **You may be eligible if...** - Your child is between 1 and 18 years old - Your child has a newly diagnosed DIPG on MRI and has not received any treatment for it yet - Your child is functional enough to participate (performance score of 50 or above) - The tumor is accessible for a precise stereotactic biopsy and injection **You may NOT be eligible if...** - Your child has had any prior treatment for DIPG - Your child has a serious infection, immune deficiency, autoimmune disease, or active hepatitis - Your child has a tumor in multiple separate locations - Your child has Li-Fraumeni syndrome or certain inherited cancer-predisposing genetic conditions - Your child's blood counts or organ function are significantly abnormal Talk to your doctor to see if this trial is right for you.